Eupraxia Therapeutics: Positive EP-104GI EoE Data, Strong Safety Profile, and Solid Cash Runway Support Buy Rating

Eupraxia Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the stock and has a $16.00 price target.

Sam Slutsky has given his Buy rating due to a combination of factors related to Eupraxia’s lead asset, EP-104GI, and its emerging clinical profile in eosinophilic esophagitis (EoE). Updated Phase 1b/2a high-dose data show that the highest tested dose is delivering robust and durable improvements in esophageal tissue health, approaching near-normal histology over 12 weeks, with a clear dose-response relationship. These tissue-level benefits are complemented by encouraging patient-reported outcomes, where a substantial proportion of patients receiving adequate esophageal coverage achieved and maintained clinically meaningful symptom improvements out to 52 weeks without treatment discontinuations. Comparisons to historical data from Dupixent suggest EP-104GI may offer competitive or potentially superior histological and symptomatic benefits, supporting the thesis that a once-yearly injectable therapy could be a differentiated treatment option in EoE.

The safety and pharmacokinetic data further reinforce the positive outlook that underpins Slutsky’s Buy recommendation. Systemic exposure to EP-104GI remains below thresholds associated with daily inhaled fluticasone, indicating that the drug is achieving its goal of localized esophageal delivery while limiting systemic steroid burden. Importantly, no serious adverse events or cases of oral candidiasis have been reported across more than 200 patient-months of exposure, supporting a favorable tolerability profile. When these encouraging clinical and safety data are considered alongside the company’s modest cash burn, roughly 2.8 years of cash runway, and low short interest, Slutsky views Eupraxia as well positioned to advance EP-104GI and drive further value creation, justifying his Buy rating on the stock.